This is a preview of subscription content, log in via an institution to check access.
Reference
Barnett JC, et al. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. Cancer : 6 Aug 2013. Available from: URL: http://dx.doi.org/10.1002/cncr.28283
Rights and permissions
About this article
Cite this article
Bevacizumab not cost effective in ovarian cancer. PharmacoEcon Outcomes News 685, 7 (2013). https://doi.org/10.1007/s40274-013-0648-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0648-3